{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:58:38Z","timestamp":1784357918866,"version":"3.55.0"},"reference-count":26,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    To assess patient characteristics, burden of disease, healthcare resource utilization and costs of acute myeloid leukemia (AML) by treatment intensity in German claims data.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    In this retrospective cohort study using claims data from the German sickness fund AOK PLUS, we identified incident AML patients between 2012 and 2022. Incident AML patients were stratified into groups receiving intensive chemotherapy (IC) or nonintensive therapy (NIC). We then conducted descriptive analyses of patient characteristics, disease burden, including blood and platelet transfusions, healthcare resource utilization and costs.\n                    <jats:bold>Results:<\/jats:bold>\n                    We identified 1533 incident AML patients who received treatment (male: 53%; mean age: 67.7\u00a0years; median Charlson comorbidity index [CCI]: 5.0), corresponding to an incidence rate of 4.4\/100,000. A total of 688 patients (44.9%) were categorized as IC, 845 patients (55.1%) as NIC. Notably, 860 additional patients (male: 48%; 78.0\u00a0years; median CCI: 5.0) had no relevant treatment code. NIC patients were older than IC patients (78.0 vs 61.0\u00a0years) and had a higher comorbidity burden (median CCI: 6.0 vs 4.0). NIC patients were hospitalized to a lesser extent (81.3% vs 87.9%), had shorter lengths of stay (64.0 vs 103.1\u00a0days\/patient-year [PY]) and lower hospitalization costs\/PY (56,063\u20ac\/PY vs 110,186\u20ac\/PY) compared with IC patients. Anemia and thrombocytopenia (NIC: 40.5 and 39.5%, IC: 76.9 and 42.6%) as well as blood and platelet transfusions were common, especially among IC patients (NIC: 93.0 and 74.3%, IC: 99.4 and 98.5%).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Compared with IC patients, NIC patients were older, had a higher comorbidity burden and fewer hospitalizations. Combined with the high number of older patients not receiving AML treatment, this points to a lack of adequate treatment options for this patient population. The high rates of blood and platelet transfusions, particularly among IC patients, underscore the high disease burden and emphasize the need for better-tolerated therapies.\n                  <\/jats:p>","DOI":"10.57264\/cer-2024-0196","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:13:40Z","timestamp":1764335620000},"source":"Crossref","is-referenced-by-count":2,"title":["Patient characteristics, burden of disease, healthcare resource utilization and costs in acute myeloid leukemia \u2013 a retrospective observational study with German claims data"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7700-163X","authenticated-orcid":false,"given":"Katja","family":"Greth","sequence":"first","affiliation":[{"name":"Cytel Inc., Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Lehne","sequence":"additional","affiliation":[{"name":"Cytel Inc., Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghiani","sequence":"additional","affiliation":[{"name":"Cytel Inc., Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmako\u00f6konomie und Arzneimittellogistik e.V. (IPAM), Wismar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Sandwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kaulfuss","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdha","family":"Gokhale","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Russell","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Sandwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"7","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky I","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 6(7), e441 (2016).","journal-title":"Blood Cancer J."},{"key":"e_1_3_8_4_2","volume-title":"SEER Cancer Stat Facts: Acute Myeloid Leukemia","unstructured":"SEER Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute, MD, USA, Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"issue":"24","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2217\/fon-2022-0786","article-title":"Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes","volume":"19","author":"Dharmani C","year":"2023","unstructured":"Dharmani C, Wang E, Tu N Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes. Future Oncol. (London, England) 19(24), 1677\u20131693 (2023).","journal-title":"Future Oncol. (London, England)"},{"issue":"10","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey EH","year":"2018","unstructured":"Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am. J. Hematol. 93(10), 1267\u20131291 (2018).","journal-title":"Am. J. Hematol."},{"key":"e_1_3_8_7_2","unstructured":"The American Cancer Society medical and editorial content team. What is acute myeloid leukemia (AML)? (2018). (updated 21 August 2018). Available from: https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/what-is-aml.html"},{"issue":"9825","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase III study","volume":"379","author":"Castaigne S","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase III study. Lancet 379(9825), 1508\u20131516 (2012).","journal-title":"Lancet"},{"issue":"7","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383(7), 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_10_2","unstructured":"GKV Spitzenverband. Krankenversicherung. (2025)."},{"key":"e_1_3_8_11_2","unstructured":"Bundesministerium f\u00fcr Gesundheit. Aufgaben und organisation der gesetzlichen Krankenversicherung. (2025). (updated 10 June). Available from: https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/grundprinzipien\/aufgaben-und-organisation-der-gkv.html"},{"key":"e_1_3_8_12_2","unstructured":"Bundesministerium f\u00fcr Gesundheit. Daten des Gesundheitswesens 2022. (2022)."},{"issue":"5","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/03008916231153698","article-title":"Acute myeloid leukemia: incidence, transplantation and survival through Italian administrative healthcare data","volume":"109","author":"Calabria S","year":"2023","unstructured":"Calabria S, Ronconi G, Dondi L Acute myeloid leukemia: incidence, transplantation and survival through Italian administrative healthcare data. Tumori 109(5), 496\u2013503 (2023).","journal-title":"Tumori"},{"issue":"1","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"2206694","DOI":"10.1080\/16078454.2023.2206694","article-title":"Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis","volume":"28","author":"Sutter T","year":"2023","unstructured":"Sutter T, Schittenhelm M, Volken T, Lehmann T. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis. Hematology 28(1), 2206694 (2023).","journal-title":"Hematology"},{"issue":"18","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson G","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113(18), 4179\u20134187 (2009).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/fon-2022-0565","article-title":"Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database","volume":"19","author":"Dharmani C","year":"2023","unstructured":"Dharmani C, Wang E, Tu N, Salas M, Kamel YM. Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database. Future Oncol. (London, England) 19(2), 159\u2013171 (2023).","journal-title":"Future Oncol. (London, England)"},{"issue":"44","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3346\/jkms.2023.38.e345","article-title":"Real-world treatment patterns and clinical outcomes in korean patients with AML ineligible for first-line intensive chemotherapy: a subanalysis of the current study, a non-interventional, retrospective chart review","volume":"38","author":"Bang SM","year":"2023","unstructured":"Bang SM, Kang KW, Song IC Real-world treatment patterns and clinical outcomes in korean patients with AML ineligible for first-line intensive chemotherapy: a subanalysis of the current study, a non-interventional, retrospective chart review. J. Korean Med. Sci. 38(44), e345 (2023).","journal-title":"J. Korean Med. Sci."},{"issue":"11","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s00432-021-03756-7","article-title":"Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)","volume":"147","author":"Hubscher E","year":"2021","unstructured":"Hubscher E, Sikirica S, Bell T Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC). J. Cancer Res. Clin. Oncol. 147(11), 3359\u20133368 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","article-title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy","volume":"63","author":"Miyamoto T","year":"2022","unstructured":"Miyamoto T, Sanford D, Tomuleasa C Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Leukemia Lymphoma 63(4), 928\u2013938 (2022).","journal-title":"Leukemia Lymphoma"},{"key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2018.06.010","article-title":"Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States","volume":"71","author":"Bell JA","year":"2018","unstructured":"Bell JA, Galaznik A, Farrelly E Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leukemia Res. 71, 27\u201333 (2018).","journal-title":"Leukemia Res."},{"issue":"3","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40258-013-0032-2","article-title":"Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs","volume":"11","author":"Meyers J","year":"2013","unstructured":"Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl. Health Econ. Health Policy 11(3), 275\u2013286 (2013).","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"11","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/ajh.20683","article-title":"Outcomes and charges of elderly patients with acute myeloid leukemia","volume":"81","author":"Katz LM","year":"2006","unstructured":"Katz LM, Howell JB, Doyle JJ Outcomes and charges of elderly patients with acute myeloid leukemia. Am. J. Hematol. 81(11), 850\u2013857 (2006).","journal-title":"Am. J. Hematol."},{"issue":"11","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/13696998.2018.1513847","article-title":"Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia","volume":"21","author":"Hagiwara M","year":"2018","unstructured":"Hagiwara M, Sharma A, Chung KC, Delea TE. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J. Med. Econ. 21(11), 1119\u20131130 (2018).","journal-title":"J. Med. Econ."},{"key":"e_1_3_8_24_2","unstructured":"R\u00f6llig C Ayuk FA Braess J Akute myeloische leuk\u00e4mie (AML). (2022)."},{"key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"107353","DOI":"10.1016\/j.leukres.2023.107353","article-title":"Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: a retrospective study using the SEER-Medicare database","volume":"132","author":"Brunner AM","year":"2023","unstructured":"Brunner AM, Huggar D, Copher R Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: a retrospective study using the SEER-Medicare database. Leukemia Res. 132, 107353 (2023).","journal-title":"Leukemia Res."},{"issue":"6","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser M","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(6), 697\u2013712 (2020).","journal-title":"Ann. Oncol."},{"issue":"5","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","article-title":"Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting","volume":"23","author":"Gershon A","year":"2023","unstructured":"Gershon A, Ma E, Xu T Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting. Clin. Lymphoma Myeloma Leuk. 23(5), e222\u2013e231 (2023).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"e_1_3_8_28_2","first-page":"849","article-title":"Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database","volume":"26","author":"Pandya BJ","year":"2020","unstructured":"Pandya BJ, Chen CC, Medeiros BC Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database. J. Manag. Care Spec. Pharm. 26(7), 849\u2013859 (2020).","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:30:56Z","timestamp":1765884656000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.57264\/cer-2024-0196"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0196","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e240196"}}